Sunday mornings I read the science press the way some people watch weather radar, half expecting a storm that never quite arrives. This week the forecast kept promising cures and delivering, on closer inspection, a Petri dish. Somewhere a set of immune cells shifted their mood under a little ultrasound, and by the time that traveled from the lab bench to the headline it had become “stop arthritis before it starts.” The experiment never went near a joint. Nobody lied, exactly. The language just got ahead of the evidence, the way it always seems to when there is a press office involved.
What stayed with me was smaller and more human. I kept noticing how often the scientist with the breakthrough also owns the company that stands to sell it. A liver compound, a longevity diet, each one genuinely interesting, each one tied to the inventor’s own ledger. That does not make the science wrong. It just means someone in the room is not a neutral party, and it is worth knowing who.
I do not want you to be cynical. I want you to be the person in the room who reads the fine print, then decides for yourself. That is the whole job, really.
Autoimmune & Inflammation
A Petri Dish of Angry Immune Cells, a Little Ultrasound, and a Very Big Headline
UAH researchers used sound waves to shift immune cells from attack mode toward repair. The press release said ‘stop arthritis before it starts.’ The experiment never touched a joint.
Metabolic & Weight
A Gut Microbe Was Feeding Ammonia to Sick Livers. A Michigan Peptide Cut Off the Supply in Monkeys.
The compound reversed severe fatty liver in monkeys by starving one ammonia-making gut bacterium. It also comes from a company its lead inventor founded, and no human has taken it for this.
The Mice Ate More and Got Leaner. The Switch Was One Amino Acid, Turned Down.
USC mice on a low-protein, methionine-tuned diet ate as many calories as the junk-food group and still lost fat, while their own bodies pumped out more GLP-1. The scientist behind it also owns the company selling longevity diets.
Brain & Aging
Anti-Tau Alzheimer’s Drugs Keep Hitting Their Target and Missing the Disease
Tau is the new headliner at the Alzheimer’s conference, but the anti-tau antibodies keep proving they bind the protein while doing nothing for patients. The clearest win so far is a blood test.